Pleiotropic effects of nifedipine on atherosclerosis

Sho Ichi Yamagishi, Kazuo Nakamura, Katsuhiko Takenaka, Takanori Matsui, Hiroyoshi Inoue

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)


Impaired endothelial cell (EC) growth and function have been proposed to be an initial event that leads to the development of atherosclerosis. There is a growing body of evidence that atherosclerosis is an inflammatory-fibroproliferative disease, and ECs are target for cytokines and growth factors released during inflammation. Recently, nifedipine, one of the most widely used dihydropyridine-based calcium antagonists (DHPs) for treatments of patients with hypertension, was shown to inhibit vascular inflammation and subsequently improve endothelial function in many cardiovascular diseases, thus slowing the development and progression of atherosclerosis. However, the molecular mechanisms underlying this are not fully understood, because ECs do not possess voltage-operated L-type calcium channels. In this review, we discuss the pleiotropic effects of nifedipine on atherosclerosis, especially focusing on its anti-oxidative properties.

Original languageEnglish
Pages (from-to)1543-1547
Number of pages5
JournalCurrent Pharmaceutical Design
Issue number12
Publication statusPublished - 2006 Apr
Externally publishedYes


  • Advanced glycation end products
  • Atherosclerosis
  • Diabetes
  • Insulin resistance
  • Nitric oxide
  • Oxidative stress

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Pleiotropic effects of nifedipine on atherosclerosis'. Together they form a unique fingerprint.

Cite this